SALES@REPORTOCEAN.COM
 +1 888 212 3539 (US - TOLL FREE)    +91 999 711 2116 (REST OF WORLD)

`
Global Real World Evidence Solutions Market, by Therapeutic Area (Cardiovascular, Oncology, Immunology), by Component (Dataset and Services), by End-User (Medical Devices, Payers, Pharmaceuticals, Providers), by Regional Outlook (U.S., Rest of North America, France, UK, Germany, Spain, Italy, Rest of Europe, China, Japan, India, Southeast Asia, Rest of Asia Pacific, GCC Countries, Southern Africa, Rest of MEA, Brazil, Rest of Latin America) - Market Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2015-2023

Global Real World Evidence Solutions Market, by Therapeutic Area (Cardiovascular, Oncology, Immunology), by Component (Dataset and Services), by End-User (Medical Devices, Payers, Pharmaceuticals, Providers), by Regional Outlook (U.S., Rest of North America, France, UK, Germany, Spain, Italy, Rest of Europe, China, Japan, India, Southeast Asia, Rest of Asia Pacific, GCC Countries, Southern Africa, Rest of MEA, Brazil, Rest of Latin America) - Market Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2015-2023

Published date: 05-10-2019  Region: Global  Pages: 125  Format: Pdf  Publisher Name: BlueWeave Consulting & Research
SKU: RO1/117/1012

The Global Real World Evidence Solutions Market is anticipated to grow at a steady rate during the forecast period. The global real-world evidence market is valued at 612.0 million in the year 2017 and projected to reach USD 1,348.1 million by the year 2023, at a CAGR of 14.3% during the forecast period. The global real-world evidence market is growing owing to several factors. The huge pharmaceutical organizations are discovered utilizing a clinico-genomic database with tumor sequencing data for disease revelation studies and focused on medication improvement. Organizations are along these lines ready to widen their sign range and lead few clinical preliminaries for the uncommon biomarker-characterized populace. In this manner, it shows the development of real-world evidence market, during the estimated time frame. This real-world evidence solutions market will demonstrate quick development because of the move from volume to esteem based consideration, expanding maturing populace and pervasiveness of incessant maladies and postponements in medication advancement and the ensuing increment being developed expenses.

The huge pharmaceutical organizations are discovered utilizing a clinico-genomic database with tumor sequencing data for disease revelation studies and focused on medication improvement. Organizations are along these lines ready to widen their sign range and lead few clinical preliminaries for the uncommon biomarker-characterized populace. In this manner, it shows the development of real-world evidence market, during the estimated time frame. The utilization of real-world evidence (RWE) bits of knowledge is in this way discovered expanding as pharma and biotech organizations understand that RWE can be significant in medication improvement and life-cycle the board and furthermore increment proficiency in advancement and cost of clinical preliminaries.

Oncology is projected to be the dominant segment in the global real world evidence solutions market during the forecast period

In view of the helpful zone, the oncology section has been represented as the biggest portion of this real-world evidence market. The enormous portion of this section can be ascribed to the high number of clinical preliminaries that led to oncology and the rising pervasiveness of malignant growth around the world. There is likewise an expanding customized prescription and an increasingly exact necessity for oncology.

North America is expected to hold the largest market share in the global real- evidence management market during the forecast period

North America is expected to have the largest market share in the global real- evidence management market, owing to the early adoption of technologies and well-established economies in the region. The US is expected to hold the largest market share in North America. Major global real- evidence management market vendors and law enforcement agencies in the US are willing to use global real- evidence management technologies for sharing, storing, and securing the evidence with private companies. SAS (US), Syneos Health (US), Anthem (US), Clinigen Group (UK), Palantir Technologies (UK), and Flatiron Health (US), IQVIA (US), ICON (Ireland), PAREXEL (US), Pharmaceutical Product Development (US), Optum (US), International Business Machines Corporation (US), Cognizant (US), Oracle (US), among others are some of the major players in the Global Real World Evidence Solutions Market.

The Global Real World Evidence Solutions Market: Competitive Insight

SAS (US), Syneos Health (US), Anthem (US), Clinigen Group (UK), Palantir Technologies (UK), and Flatiron Health (US), IQVIA (US), ICON (Ireland), PAREXEL (US), Pharmaceutical Product Development (US), Optum (US), International Business Machines Corporation (US), Cognizant (US), Oracle (US), among others are some of the major players in the Global Real World Evidence Solutions Market.

Don't miss the business opportunity of Global Real World Evidence Solutions Market.Consult to our analyst and gain crucial insights and facilitate your business growth.

The in-depth analysis of the report provides the growth potential, upcoming trends and statistics of global Real World Evidence Solutions market size & forecast. The report promises to provide state-of-the-art technology of Real World Evidence Solutions production and industry insights which help decision makers to take sound strategic decisions. Furthermore, the report also analyzes the market drivers and challenges and competitive analysis of the market.

1. Research Framework
1.1. Research Objective
1.2. Product Overview
1.3. Market Segmentation
2. Research Methodology
3. Executive Summary
4. Industry Insights
4.1. Industry Impact and Forces
4.1.1. Growth Drivers
4.1.2. Challenges
4.1.3. Trends
4.2. Technology Landscape
4.3. Regulatory Framework
4.4. Company Share Analysis, 2018
4.5. Growth potential Analysis
4.6. Strategic Outlook
4.7. Porter's analysis
4.8. PESTEL analysis
5. Global Real World Evidence Solutions Market Overview
5.1. Market Size & Forecast
5.1.1. By Value (USD Million)
5.2. Market Share & Forecast
5.2.1. By Therapeutic Area
5.2.1.1. Cardiovascular
5.2.1.2. Oncology
5.2.1.3. Immunology
5.2.2. By Component
5.2.2.1. Dataset
5.2.2.2. Services
5.2.3. By End-User
5.2.3.1. Medical Devices
5.2.3.2. Payers
5.2.3.3. Pharmaceuticals
5.2.3.4. Providers
5.2.4. By Region
5.2.4.1. North America
5.2.4.2. Europe
5.2.4.3. Asia Pacific
5.2.4.4. South America
5.2.4.5. Middle East & Africa
6. North America Real World Evidence Solutions Market Overview
6.1. Market Size & Forecast, 2015-2025
6.1.1. By Value (USD Million)
6.2. Market Share & Forecast
6.2.1. By Therapeutic Area
6.2.2. By Component
6.2.3. By End-User
6.2.4. By Country
6.2.4.1. US
6.2.4.2. Canada
7. Europe Real World Evidence Solutions Market Overview
7.1. Market Size & Forecast, 2015-2025
7.1.1. By Value (USD Million)
7.2. Market Share & Forecast
7.2.1. By Therapeutic Area
7.2.2. By Component
7.2.3. By End-User
7.2.4. By Country
7.2.4.1. Germany
7.2.4.2. UK
7.2.4.3. France
7.2.4.4. Italy
7.2.4.5. Spain
8. Asia Pacific Real World Evidence Solutions Market Overview
8.1. Market Size & Forecast, 2015-2025
8.1.1. By Value (USD Million)
8.2. Market Share & Forecast
8.2.1. By Therapeutic Area
8.2.2. By Component
8.2.3. By End-User
8.2.4. By Country
8.2.4.1. China
8.2.4.2. India
8.2.4.3. Japan
8.2.4.4. Southeast Asia
9. Latin America Real World Evidence Solutions Market Overview
9.1. Market Size & Forecast, 2015-2025
9.1.1. By Value (USD Million)
9.2. Market Share & Forecast
9.2.1. By Therapeutic Area
9.2.2. By Component
9.2.3. By End-User
9.2.4. By Country
9.2.4.1. Brazil
9.2.4.2. Argentina
10. Middle East & Africa Real World Evidence Solutions Market Overview
10.1. Market Size & Forecast, 2015-2025
10.1.1. By Value (USD Million)
10.2. Market Share & Forecast
10.2.1. By Therapeutic Area
10.2.2. By Component
10.2.3. By End-User
10.2.4. By Country
10.2.4.1. Saudi Arabia
10.2.4.2. UAE
10.2.4.3. South Africa
11. Company Profile (Company Overview, Financial Matrix, Key Product landscape, Key Personnel, Key Competitors, Contact Address, SWOT Analysis and Strategic Outlook)
11.1. SAS
11.2. Syneos Health
11.3. Anthem
11.4. Clinigen Group
11.5. Palantir Technologies
11.6. Flatiron Health
11.7. IQVIA
11.8. ICON
11.9. PAREXEL
11.10. Pharmaceutical Product Development
11.11. Optum
11.12. International Business Machines Corporation
11.13. Cognizant
11.14. Oracle
11.15. Other Prominent Players
*Financial Details Not Be Captured in Case of Unlisted Companies
The segmentation and the companies are subjected to modifications based on in-depth secondary for the final deliverable


All Fields are mandatory*

Name: *
Email Id: *
Job Title: *
Company: *
Phone: *
Country: *
Message: *

PLEASE SELECT A LICENSE TYPE

Single User $5150
Corporate User $8000

Related Reports


Scroll to Top